{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:08:29Z","timestamp":1791889709635,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004484","name":"tehran university of medical sciences and health services","doi-asserted-by":"publisher","award":["43315"],"award-info":[{"award-number":["43315"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-\u03b1, asprosin and adiponectin were assessed using ELISA kits.<\/jats:p>\n                <jats:p>Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84\u2009\u00b1\u20092.08 versus 5.02\u2009\u00b1\u20091.29\u2009\u03bcg\/mL, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u00a00.001). Similarly, serum TNF-\u03b1, and IL-6 elevated in CAD group significantly (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u00a00.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), after adjusting for potential confounders (age, sex and BMI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01514-9","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T16:04:49Z","timestamp":1629561889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study"],"prefix":"10.1186","volume":"20","author":[{"given":"Nariman","family":"Moradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Zahraa","family":"Fouani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Vatannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Bakhti Arani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Shahrzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-1137","authenticated-orcid":false,"given":"Reza","family":"Fadaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"key":"1514_CR1","first-page":"e9349","volume":"12","author":"MA Khan","year":"2020","unstructured":"Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi S, AlKatheeri R, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020;12:e9349.","journal-title":"Cureus"},{"key":"1514_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-018-5806-x","volume":"18","author":"A Gheorghe","year":"2018","unstructured":"Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low-and middle-income countries: a systematic review. BMC Public Health. 2018;18:1.","journal-title":"BMC Public Health"},{"key":"1514_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11883-016-0575-4","volume":"18","author":"T Mandviwala","year":"2016","unstructured":"Mandviwala T, Khalid U, Deswal A. Obesity and cardiovascular disease: a risk factor or a risk marker? Curr Atheroscler Rep. 2016;18:21.","journal-title":"Curr Atheroscler Rep"},{"key":"1514_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1586\/14779072.2.2.193","volume":"2","author":"P Poirier","year":"2004","unstructured":"Poirier P, Martin J, Marceau P, Biron S, Marceau S. Impact of bariatric surgery on cardiac structure, function and clinical manifestations in morbid obesity. Expert Rev Cardiovasc Ther. 2004;2:193\u2013201.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1514_CR5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","volume":"113","author":"P Poirier","year":"2006","unstructured":"Poirier P, Giles T, Bray G, Hong Y, Stern J, Pi-Sunyer X, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation. 2006;113:898\u2013918.","journal-title":"Circulation"},{"key":"1514_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R. Atherosclerosis\u2013an inflammatory disease. N Engl J Med. 1999;340:115\u201326.","journal-title":"N Engl J Med"},{"key":"1514_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced Glucogenic protein hormone. Cell. 2016;165:566\u201379.","journal-title":"Cell"},{"key":"1514_CR8","doi-asserted-by":"publisher","first-page":"e49530","DOI":"10.15252\/embr.201949530","volume":"21","author":"Y Yu","year":"2020","unstructured":"Yu Y, He JH, Hu LL, Jiang LL, Fang L, Yao GD, et al. Placensin is a glucogenic hormone secreted by human placenta. EMBO Rep. 2020;21:e49530.","journal-title":"EMBO Rep"},{"key":"1514_CR9","doi-asserted-by":"publisher","first-page":"101397","DOI":"10.1016\/j.tice.2020.101397","volume":"66","author":"N Kocaman","year":"2020","unstructured":"Kocaman N, Kulo\u011flu T. Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue Cell. 2020;66:101397.","journal-title":"Tissue Cell"},{"key":"1514_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/nm.4432","volume":"23","author":"C Duerrschmid","year":"2017","unstructured":"Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444\u201353.","journal-title":"Nat Med"},{"key":"1514_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00421-020-04570-8","volume":"121","author":"AN Leonard","year":"2020","unstructured":"Leonard AN, Shill AL, Thackray AE, Stensel DJ, Bishop NC. Fasted plasma asprosin concentrations are associated with menstrual cycle phase, oral contraceptive use and training status in healthy women. Eur J Appl Physiol. 2020;121:793\u2013801.","journal-title":"Eur J Appl Physiol"},{"key":"1514_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/JME-20-0218","volume":"66","author":"ERS Maylem","year":"2020","unstructured":"Maylem ERS, Spicer LJ, Batalha I, Schutz LF. Discovery of a possible role of asprosin in ovarian follicular function. J Mol Endocrinol. 2020;66:35\u201344.","journal-title":"J Mol Endocrinol"},{"key":"1514_CR13","doi-asserted-by":"publisher","first-page":"20888","DOI":"10.1002\/jcp.28694","volume":"234","author":"TW Jung","year":"2019","unstructured":"Jung TW, Kim HC, Kim HU, Park T, Park J, Kim U, et al. Asprosin attenuates insulin signaling pathway through PKCdelta-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019;234:20888\u201399.","journal-title":"J Cell Physiol"},{"key":"1514_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mce.2019.03.001","volume":"486","author":"T Lee","year":"2019","unstructured":"Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96\u2013104.","journal-title":"Mol Cell Endocrinol"},{"key":"1514_CR15","doi-asserted-by":"publisher","first-page":"e1023","DOI":"10.1002\/mgg3.1023","volume":"8","author":"M Lin","year":"2020","unstructured":"Lin M, Liu Z, Liu G, Zhao S, Li C, Chen W, et al. Genetic and molecular mechanism for distinct clinical phenotypes conveyed by allelic truncating mutations implicated in FBN1. Mol Genet Genomic Med. 2020;8:e1023.","journal-title":"Mol Genet Genomic Med"},{"key":"1514_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/10520295.2019.1656344","volume":"95","author":"N Kocaman","year":"2020","unstructured":"Kocaman N, Artas G. Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma? Biotech Histochem. 2020;95:171\u20135.","journal-title":"Biotech Histochem"},{"key":"1514_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.mehy.2018.07.008","volume":"118","author":"MM Donma","year":"2018","unstructured":"Donma MM, Donma O. Asprosin: possible target in connection with ghrelin and cytokine network expression in the post-burn treatment. Med Hypotheses. 2018;118:163\u20138.","journal-title":"Med Hypotheses"},{"key":"1514_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cca.2017.10.034","volume":"489","author":"L Zhang","year":"2017","unstructured":"Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2017;489:183\u20138.","journal-title":"Clin Chim Acta"},{"key":"1514_CR19","doi-asserted-by":"publisher","first-page":"9471583","DOI":"10.1155\/2018\/9471583","volume":"2018","author":"Y Wang","year":"2018","unstructured":"Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y, et al. Plasma Asprosin concentrations are increased in individuals with glucose Dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediat Inflamm. 2018;2018:9471583.","journal-title":"Mediat Inflamm"},{"key":"1514_CR20","doi-asserted-by":"publisher","first-page":"7375294","DOI":"10.1155\/2018\/7375294","volume":"2018","author":"X Li","year":"2018","unstructured":"Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, et al. Plasma Asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediat Inflamm. 2018;2018:7375294.","journal-title":"Mediat Inflamm"},{"key":"1514_CR21","doi-asserted-by":"publisher","first-page":"e0222771","DOI":"10.1371\/journal.pone.0222771","volume":"14","author":"JB Groener","year":"2019","unstructured":"Groener JB, Valkanou A, Kender Z, Pfeiffenberger J, Kihm L, Fleming T, et al. Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS One. 2019;14:e0222771.","journal-title":"PLoS One"},{"key":"1514_CR22","doi-asserted-by":"publisher","first-page":"170132","DOI":"10.1016\/j.peptides.2019.170132","volume":"120","author":"Y Baykus","year":"2019","unstructured":"Baykus Y, Yavuzkir S, Ustebay S, Ugur K, Deniz R, Aydin S. Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus. Peptides. 2019;120:170132.","journal-title":"Peptides"},{"key":"1514_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000503808","volume":"75","author":"M Wang","year":"2019","unstructured":"Wang M, Yin C, Wang L, Liu Y, Li H, Li M, et al. Serum Asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 2019;75:205\u201312.","journal-title":"Ann Nutr Metab"},{"key":"1514_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/09513590.2018.1512967","volume":"35","author":"M Alan","year":"2019","unstructured":"Alan M, Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35:220\u20133.","journal-title":"Gynecol Endocrinol"},{"key":"1514_CR25","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0735-1097(99)00126-6","volume":"33","author":"PJ Scanlon","year":"1999","unstructured":"Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al. ACC\/AHA guidelines for coronary angiography. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (committee on coronary angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol. 1999;33:1756\u2013824.","journal-title":"J Am Coll Cardiol"},{"key":"1514_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"1514_CR27","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.ajem.2017.12.032","volume":"36","author":"AC Acara","year":"2018","unstructured":"Acara AC, Bolatkale M, K\u0131z\u0131lo\u011flu \u0130, \u0130bi\u015fo\u011flu E, Can \u00c7. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin. Am J Emerg Med. 2018;36:1504\u20135.","journal-title":"Am J Emerg Med"},{"key":"1514_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12872-020-01680-1","volume":"20","author":"MS Wen","year":"2020","unstructured":"Wen MS, Wang CY, Yeh JK, Chen CC, Tsai ML, Ho MY, et al. The role of Asprosin in patients with dilated cardiomyopathy. BMC Cardiovasc Disord. 2020;20:402.","journal-title":"BMC Cardiovasc Disord"},{"key":"1514_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s11739-019-02082-8","volume":"14","author":"F Gragnano","year":"2019","unstructured":"Gragnano F, Fimiani F, Di Maio M, Cesaro A, Limongelli G, Cattano D, et al. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med. 2019;14:621\u20135.","journal-title":"Intern Emerg Med"},{"key":"1514_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12933-019-0826-0","volume":"18","author":"FC Sasso","year":"2019","unstructured":"Sasso FC, Pafundi PC, Marfella R, Calabr\u00f2 P, Piscione F, Furbatto F, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE study. Cardiovasc Diabetol. 2019;18:24.","journal-title":"Cardiovasc Diabetol"},{"key":"1514_CR31","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1570161115666170201114835","volume":"15","author":"F Gragnano","year":"2017","unstructured":"Gragnano F, Golia E, Natale F, Bianchi R, Pariggiano I, Crisci M, et al. Von Willebrand factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol. 2017;15:404\u201315.","journal-title":"Curr Vasc Pharmacol"},{"key":"1514_CR32","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3389\/fimmu.2019.02163","volume":"10","author":"O Gruzdeva","year":"2019","unstructured":"Gruzdeva O, Uchasova E, Dyleva Y, Borodkina D, Akbasheva O, Antonova L, et al. Adipocytes directly affect coronary artery disease pathogenesis via induction of Adipokine and cytokine imbalances. Front Immunol. 2019;10:2163.","journal-title":"Front Immunol"},{"key":"1514_CR33","doi-asserted-by":"crossref","unstructured":"Sinitsky MY, Dyleva YA, Uchasova EG, Belik EV, Yuzhalin AE, Gruzdeva OV, et al. Adipokine gene expression in adipocytes isolated from different fat depots of coronary artery disease patients. Arch Physiol Biochem. 2019:1\u20139. Online ahead of print.","DOI":"10.1080\/13813455.2019.1674338"},{"key":"1514_CR34","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1002\/jcp.28350","volume":"234","author":"AK Malakar","year":"2019","unstructured":"Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234:16812\u201323.","journal-title":"J Cell Physiol"},{"key":"1514_CR35","doi-asserted-by":"publisher","first-page":"2521096","DOI":"10.1155\/2019\/2521096","volume":"2019","author":"K Ugur","year":"2019","unstructured":"Ugur K, Aydin S. Saliva and blood Asprosin hormone concentration associated with obesity. Int J Endocrinol. 2019;2019:2521096.","journal-title":"Int J Endocrinol"},{"key":"1514_CR36","doi-asserted-by":"crossref","unstructured":"Ozcan S, Ulker N, Bulmus O, Yardimci A, Ozcan M, Canpolat S. The modulatory effects of irisin on asprosin, leptin, glucose levels and lipid profile in healthy and obese male and female rats. Arch Physiol Biochem. 2020:1\u20138. Online ahead of print","DOI":"10.1080\/13813455.2020.1722706"},{"key":"1514_CR37","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s41366-018-0248-1","volume":"43","author":"CY Wang","year":"2019","unstructured":"Wang CY, Lin TA, Liu KH, Liao CH, Liu YY, Wu VC, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes. 2019;43:1019\u201325.","journal-title":"Int J Obes"},{"key":"1514_CR38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/jcm8050666","volume":"8","author":"JR Ko","year":"2019","unstructured":"Ko JR, Seo DY, Kim TN, Park SH, Kwak HB, Ko KS, et al. Aerobic exercise training decreases hepatic Asprosin in diabetic rats. J Clin Med. 2019;8:666.","journal-title":"J Clin Med"},{"key":"1514_CR39","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1080\/07420528.2020.1792482","volume":"37","author":"H Ceylan","year":"2020","unstructured":"Ceylan H, Sayg\u0131n \u00d6, \u00d6zel T\u00fcrkc\u00fc \u00dc. Assessment of acute aerobic exercise in the morning versus evening on asprosin, spexin, lipocalin-2, and insulin level in overweight\/obese versus normal weight adult men. Chronobiol Int. 2020;37:1252\u201368.","journal-title":"Chronobiol Int"},{"key":"1514_CR40","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40519-020-00845-3","volume":"26","author":"Y Hu","year":"2020","unstructured":"Hu Y, Xu Y, Zheng Y, Kang Q, Lou Z, Liu Q, et al. Increased plasma asprosin levels in patients with drug-naive anorexia nervosa. Eat Weight Disord. 2020;26:313\u201321.","journal-title":"Eat Weight Disord"},{"key":"1514_CR41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00520-020-05621-8","volume":"29","author":"C Du","year":"2020","unstructured":"Du C, Wang C, Guan X, Li J, Du X, Xu Z, et al. Asprosin is associated with anorexia and body fat mass in cancer patients. Support Care Cancer. 2020;29:1369\u201375.","journal-title":"Support Care Cancer"},{"key":"1514_CR42","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1038\/s41598-019-42061-9","volume":"9","author":"CL Chang","year":"2019","unstructured":"Chang CL, Huang SY, Hsu YC, Chin TH, Soong YK. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Sci Rep. 2019;9:6447.","journal-title":"Sci Rep"},{"key":"1514_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000500523","volume":"91","author":"W Long","year":"2019","unstructured":"Long W, Xie X, Du C, Zhao Y, Zhang C, Zhan D, et al. Decreased circulating levels of Asprosin in obese children. Horm Res Paediatr. 2019;91:271\u20137.","journal-title":"Horm Res Paediatr"},{"key":"1514_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ped.14176","volume":"62","author":"E Sunnetci Silistre","year":"2020","unstructured":"Sunnetci Silistre E, Hatipoglu HU. Increased serum circulating Asprosin levels in children with obesity. Pediatr Int. 2020;62:467\u201376.","journal-title":"Pediatr Int"},{"key":"1514_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13098-020-00564-w","volume":"12","author":"S Naiemian","year":"2020","unstructured":"Naiemian S, Naeemipour M, Zarei M, Lari Najafi M, Gohari A, Behroozikhah MR, et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020;12:65.","journal-title":"Diabetol Metab Syndr"},{"key":"1514_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2337\/diacare.2.2.154","volume":"2","author":"TA Welborn","year":"1979","unstructured":"Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154\u201360.","journal-title":"Diabetes Care"},{"key":"1514_CR47","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jacc.2009.10.060","volume":"55","author":"ES Ford","year":"2010","unstructured":"Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"1514_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cmet.2019.05.022","volume":"30","author":"E Li","year":"2019","unstructured":"Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y, et al. OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin. Cell Metab. 2019;30:319\u2013328.e318.","journal-title":"Cell Metab"},{"key":"1514_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/jcp.29835","volume":"236","author":"R Wang","year":"2021","unstructured":"Wang R, Hu W. Asprosin promotes \u03b2-cell apoptosis by inhibiting the autophagy of \u03b2-cell via AMPK-mTOR pathway. J Cell Physiol. 2021;236:215\u201321.","journal-title":"J Cell Physiol"},{"key":"1514_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5603\/EP.a2020.0059","volume":"72","author":"N Gozel","year":"2020","unstructured":"Gozel N, Kilinc F. Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin. Endokrynol Pol. 2020;72:37\u201343.","journal-title":"Endokrynol Pol"},{"key":"1514_CR51","first-page":"1","volume":"41","author":"R Deniz","year":"2020","unstructured":"Deniz R, Yavuzkir S, Ugur K, Ustebay DU, Baykus Y, Ustebay S, et al. Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. J Obstet Gynaecol. 2020;41:1\u20136.","journal-title":"J Obstet Gynaecol"},{"key":"1514_CR52","doi-asserted-by":"publisher","first-page":"155184","DOI":"10.1016\/j.cyto.2020.155184","volume":"134","author":"F Ke","year":"2020","unstructured":"Ke F, Xue G, Jiang X, Li F, Lai X, Zhang M, et al. Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine. 2020;134:155184.","journal-title":"Cytokine"},{"key":"1514_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.placenta.2020.02.004","volume":"93","author":"L Zhong","year":"2020","unstructured":"Zhong L, Long Y, Wang S, Lian R, Deng L, Ye Z, et al. Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: a nested case-control study. Placenta. 2020;93:17\u201322.","journal-title":"Placenta"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01514-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01514-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01514-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T22:04:38Z","timestamp":1675634678000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01514-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01514-9","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The written informed consent was signed by all the participants and the research was confirmed by the Ethics Committee of Tehran University of Medical Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}